Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light von Wessels, Mark HJ, Van Lierop, Zoë YGJ, Noteboom, Samantha, Strijbis, Eva MM, Heijst, Johannes A, Van Kempen, Zoé LE, Moraal, Bastiaan, Barkhof, Frederik, Uitdehaag, Bernard MJ, Schoonheim, Menno M, Killestein, Joep, Teunissen, Charlotte E

Volltext

Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic von van Lierop, Zoë YGJ, Wessels, Mark HJ, Lekranty, Womei ML, Moraal, Bastiaan, Hof, Sam N, Hogenboom, Laura, de Jong, Brigit A, Meijs, Nandi, Mensing, Liselore A, van Oosten, Bob W, Sol, Nik, van Kempen, Zoé LE, Vermunt, Lisa, Willems, Myrthe J, Strijbis, Eva MM, Uitdehaag, Bernard MJ, Killestein, Joep, Teunissen, Charlotte E

Volltext

Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients von Toorop, Alyssa A, Wessels, Mark HJ, Boonkamp, Lynn, Gelissen, Liza MY, Hoitsma, E, Zeinstra, Esther MPE, van Rooij, Luuk C, van Munster, Caspar EP, Vennegoor, Anke, Mostert, Jop P, Wokke, Beatrijs HA, Kalkers, Nynke F, Hoogervorst, Erwin LJ, van Eijk, Jeroen JJ, Roosendaal, Christiaan M, Kragt, Jolijn J, Eurelings, Marijke, van Genugten, Jessie, Nielsen, Jessica, Sinnige, LGF, Kloosterziel, Mark E, Arnoldus, Edo PJ, van Dijk, Gert W, Bouvy, Willem H, Strijbis, Eva MM, van Oosten, Bob W, de Jong, Brigit A, Uitdehaag, Bernard MJ, Rispens, Theo, Killestein, Joep, van Kempen, Zoé LE, Teunissen, Charlotte E

Volltext

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light von Wessels, Mark Hj, Van Lierop, Zoë YGJ, Noteboom, Samantha, Strijbis, Eva MM, Heijst, Johannes A, Van Kempen, Zoé LE, Moraal, Bastiaan, Barkhof, Frederik, Uitdehaag, Bernard MJ, Schoonheim, Menno M, Killestein, Joep, Teunissen, Charlotte E

Volltext bestellen

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS) von Toorop, Alyssa A, van Lierop, Zoë Ygj, Gelissen, Liza My, Hoitsma, Elske, Zeinstra, Esther Mpe, van Rooij, Luuk C, van Munster, Caspar Ep, Vennegoor, Anke, Mostert, Jop P, Wokke, Beatrijs Ha, Kalkers, Nynke F, Hoogervorst, Erwin Lj, van Eijk, Jeroen Jj, Roosendaal, Christiaan M, Kragt, Jolijn J, Eurelings, Marijke, van Genugten, Jessie, Nielsen, Jessica, Sinnige, Lgf, Kloosterziel, Mark E, Arnoldus, Edo Pj, van Dijk, Gert W, Bouvy, Willem H, Wessels, Mark Hj, Boonkamp, Lynn, Strijbis, Eva Mm, van Oosten, Bob W, De Jong, Brigit A, Lissenberg-Witte, Birgit I, Barkhof, Frederik, Moraal, Bastiaan, Teunissen, Charlotte E, Rispens, Theo, Uitdehaag, Bernard Mj, Killestein, Joep, van Kempen, Zoé LE

Volltext bestellen